新型β-内酰胺酶抑制剂纳库巴坦和齐他巴坦提高β-内酰胺类抗生素对脓肿分枝杆菌复合体临床分离株的活性。
New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.
机构信息
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00733-19. Print 2019 Sep.
Abstract
The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve the activity of β-lactam antibiotics against bacteria of the complex (MABC). Here, we evaluated the activities of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner β-lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other β-lactams, similar to prior results with avibactam and relebactam.
摘要
新型的二氮杂二环辛烷类β-内酰胺酶抑制剂阿维巴坦和雷利巴坦提高了β-内酰胺类抗生素对复杂（MABC）细菌的活性。在这里，我们评估了两种处于临床开发阶段的新型二氮杂二环辛烷类β-内酰胺酶抑制剂纳库巴坦和齐他巴坦与β-内酰胺类药物对 MABC 临床分离株的活性。这两种抑制剂都降低了其β-内酰胺类药物（美罗培南（8 倍）和头孢吡肟（2 倍））的 MIC 值，以及其他β-内酰胺类药物的 MIC 值，这与阿维巴坦和雷利巴坦的先前结果相似。
相似文献
1
New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00733-19. Print 2019 Sep.
2
Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02623-18. Print 2019 Mar.
3
Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):339-354. doi: 10.1007/s10096-023-04732-4. Epub 2023 Dec 14.
4
In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex.
Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. doi: 10.1016/j.ijantimicag.2022.106669. Epub 2022 Sep 3.
5
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Int J Antimicrob Agents. 2024 May;63(5):107150. doi: 10.1016/j.ijantimicag.2024.107150. Epub 2024 Mar 19.
6
Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa.
J Antimicrob Chemother. 2024 Oct 1;79(10):2591-2597. doi: 10.1093/jac/dkae263.
7
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01238-17. Print 2017 Nov.
8
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
J Antimicrob Chemother. 2017 May 1;72(5):1373-1385. doi: 10.1093/jac/dkw593.
9
Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab β-lactamase on the in vitro and intracellular efficacy of imipenem.
J Antimicrob Chemother. 2020 Feb 1;75(2):379-383. doi: 10.1093/jac/dkz433.
10
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31.
引用本文的文献
1
Novel C5α-substituted carbapenems enhance killing via selective target binding and reduced hydrolysis by Bla.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0017025. doi: 10.1128/aac.00170-25. Epub 2025 Jun 17.
2
Durlobactam in combination with β-lactams to combat .
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0117424. doi: 10.1128/aac.01174-24. Epub 2024 Dec 23.
3
Durlobactam to boost the clinical utility of standard of care β-lactams against lung disease.
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0104624. doi: 10.1128/aac.01046-24. Epub 2024 Nov 20.
4
Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare.
J Antimicrob Chemother. 2024 Nov 4;79(11):2731-2741. doi: 10.1093/jac/dkae288.
5
New Agents Are Coming, and So Is the Resistance.
Antibiotics (Basel). 2024 Jul 13;13(7):648. doi: 10.3390/antibiotics13070648.
6
effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical isolates.
Microbiol Spectr. 2024 Jul 2;12(7):e0008424. doi: 10.1128/spectrum.00084-24. Epub 2024 Jun 6.
7
Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.
Front Microbiol. 2024 Feb 6;15:1331508. doi: 10.3389/fmicb.2024.1331508. eCollection 2024.
8
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.
Infection. 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8.
9
Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.
Curr Top Med Chem. 2024;24(15):1291-1326. doi: 10.2174/0115680266276938240108060247.
10
Chemical genetic approaches for the discovery of bacterial cell wall inhibitors.
RSC Med Chem. 2023 Aug 30;14(11):2125-2154. doi: 10.1039/d3md00143a. eCollection 2023 Nov 15.
本文引用的文献
1
Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of .
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00470-19. Print 2019 Jun.
2
Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex .
mBio. 2019 Feb 12;10(1):e02895-18. doi: 10.1128/mBio.02895-18.
3
Select β-Lactam Combinations Exhibit Synergy against .
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02613-18. Print 2019 Apr.
4
Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02623-18. Print 2019 Mar.
5
Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.02596-17. Print 2018 Sep.
6
Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00682-18. Print 2018 Aug.
7
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
8
Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00866-17. Print 2017 Oct.
9
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. doi: 10.1093/jac/dkx050.
10
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.
Future Microbiol. 2017 May;12(6):473-480. doi: 10.2217/fmb-2016-0234. Epub 2017 Feb 16.
Zotero 插件